• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Cantor Fitzgerald sets $20 price target for Core Scientific stock: Should you buy?

by July 18, 2024
written by July 18, 2024

Core Scientific Inc (NASDAQ: CORZ) has recently been garnering a lot of attention from financial analysts. On Wednesday, Cantor Fitzgerald initiated coverage of the company, assigning an “overweight” rating with a compelling $20.00 price target.

This suggests a substantial upside of nearly 71% from the current stock price, signaling strong confidence in the company’s future prospects.

Concurrently, today B. Riley Securities upgraded their rating on Core Scientific from Neutral to Buy, driven by the company’s strategic expansion into high-performance computing (HPC) hosting.

The upgrade by B. Riley Securities stems from Core Scientific’s recent deals, particularly with CoreWeave. Analyst Lucas Pipes highlighted the company’s potential to become a leader in the HPC space.

This optimism is supported by a series of long-term contracts with CoreWeave, expected to generate over $3.5 billion in revenue across the next 12 years.

These contracts not only signify a robust revenue stream but also mark a strategic pivot towards leveraging Core Scientific’s extensive infrastructure for AI data centers—a growing industry demand.

Bernstein analyst Gautam Chhugani also provided a positive outlook on July 10th, starting coverage of Core Scientific with an “Outperform” rating.

Chhugani emphasized the company’s ideal setup for AI data center collaboration due to its power infrastructure and operational capabilities.

He anticipates a significant portion of the company’s power capacity, about 20%, transitioning to support AI by 2027, reinforcing the strategic shift towards diversified high-value compute services.

Financial performance and business challenges

Core Scientific’s financial results underscores these strategic advancements. The company reported a GAAP EPS of $0.78 for Q1 2024, with revenue reaching $179.29 million, marking a 48.6% increase year-over-year.

This robust financial performance is rooted in both its traditional bitcoin mining operations and its burgeoning HPC services, with a net income of $210.7 million highlighting operational efficiency and profitability.

However, Core Scientific’s journey has seen its challenges. Despite the strategic expansions, the company faced a momentary dip when it updated its June production figures, showing a decrease in bitcoin mined compared to the previous month.

Yet, this was quickly overshadowed by the overall positive momentum driven by analyst upgrades and operational successes.

CoreWeave’s bid

In a notable event earlier in June, Core Scientific rejected an unsolicited proposal from CoreWeave to acquire the company at $5.75 per share, which it considered undervalued.

This proposal came shortly after Core Scientific disclosed the lucrative 12-year contracts with CoreWeave, indicating significant external interest and perceived value in Core Scientific’s operational and strategic direction.

This series of developments—from analyst upgrades, strategic pivots towards HPC hosting, to handling unsolicited acquisition offers—positions Core Scientific positively in the eyes of investors.

With all these facets considered, Core Scientific represents a multifaceted investment opportunity, poised for potential growth in both its established and emerging business areas.

Now, as we turn toward the technical analysis, we will assess how these fundamental strengths and strategic initiatives are reflected in Core Scientific’s stock price movements and what the charts might indicate about its future trajectory.

Super strong short-term momentum

In January this year, Core Scientific emerged from bankruptcy, completed its reorganization process and relisted its shares on the Nasdaq.

The stock entered a bullish phase in May this year when it was trading below $3.

CORZ by TradingView

Following the bid from CoreWeave, the stock skyrocketed in June and that strong rally has resulted in it appreciating more than 400% from its April lows.

The stock continues to enjoy strong bullish momentum hence short-term traders must refrain from shorting it currently.

Investors who are bullish on the company’s prospects and are looking to enter long positions must try to accumulate it at levels below $11 with a stop loss at $8.9, which has been acting as a strong support since late June.

If the bullish momentum continues, the stock might reach the price target assigned by Cantor Fitzgerald in the coming months.

The post Cantor Fitzgerald sets $20 price target for Core Scientific stock: Should you buy? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Ripple and Tron: Ripple is moving to the bearish side again
next post
Render (RNDR) hits crucial user milestone ahead of much-anticipated token swap

related articles

Asian markets close: Nikkei, Kospi down; Sensex closes...

May 19, 2025

Qualcomm unveils AI chips for data centres with...

May 19, 2025

Best crypto to buy now: Bitcoin Pepe leads...

May 19, 2025

JPMorgan cuts Netflix rating, citing balanced risk-reward post-rally;...

May 19, 2025

Bitcoin ETF open interest dips 5% to $29.47B...

May 19, 2025

US stocks slip in the red on Monday:...

May 19, 2025

Should Klarna IPO remain on watch list after...

May 19, 2025

Why this brokerage downgraded UnitedHealth’s rating to ‘hold’

May 19, 2025

Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint...

May 19, 2025

Cathie Wood says Trump’s tariffs could unlock tech...

May 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump accepts second state visit to UK, reveals letter from King Charles

    February 27, 2025
  • HHS will reevaluate programs, regulations to ensure taxpayer funds are not paying for elective abortions

    January 28, 2025
  • Dems renew push for limiting presidential clemency powers after Hunter Biden pardon

    December 4, 2024
  • Biden DOJ to accuse Russia of trying to influence 2024 presidential election: report

    September 4, 2024
  • Israel denies entry to two British lawmakers accused of planning to ‘spread anti-Israel hatred’

    April 7, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,745)
  • Investing (624)
  • Stock (775)

Latest Posts

  • North Korea expands list of crimes punishable by death: report

    September 28, 2024
  • DOGE slashes billions more in expenses for programs like Peruvian climate change and gender equity in Mexico

    March 27, 2025
  • Disgraced lawyer Michael Avenatti seeks mercy at resentencing, citing ‘model inmate’ record

    May 7, 2025

Recent Posts

  • ‘Progressively Worse’: Kamala Harris, Joe Biden, ‘The Squad’ — they’re not your daddy’s Democrats

    July 30, 2024
  • UK’s Starmer juggles trouble at home as he walks geopolitical tightrope with Trump

    February 27, 2025
  • Trump admin removes Biden-era transportation safety board vice chair

    May 6, 2025

Editor’s Pick

  • Nikki Haley slams PAC using her name to support Harris as group targets Wisconsin Republicans

    September 12, 2024
  • Revolut announces $45 billion share sale to staff

    August 2, 2024
  • Zyn-maker Philip Morris announces $600 million Colorado facility to ramp up production

    July 17, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock